Letter to the Editor

Regarding “Efficacy of Stellate Ganglion Blockade for the Management of Type 1 Complex Regional Pain Syndrome”

Authors: Kosmas I. Paraskevas, MD, FASA, Alexandra A. Michaloglou, MD, Maria Samara, MD, Despina D. Briana, MD

Abstract

To the Editor:


We read with interest the article by Ackerman and Zhang1 examining the efficacy of stellate ganglion blockade (SGB) in patients with complex regional pain syndrome type I (CRPS I) of the hand.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Ackerman WE, Zhang JM. Efficacy of stellate ganglion blockade for the management of type 1 complex regional pain syndrome. South Med J 2006;99:1084–1088.
 
2. Paraskevas KI, Michaloglou AA, Briana DD, et al. Treatment of complex regional pain syndrome type I of the hand with a series of intravenous regional sympathetic blocks with guanethidine and lidocaine. Clin Rheumatol 2006;25:687–693.
 
3. Bonelli S, Conoscente F, Movilia PG, et al. Regional intravenous guanethidine vs stellate ganglion block in reflex sympathetic dystrophies: a randomized trial. Pain 1983;16:297–307.